138,105 Shares in Hims & Hers Health, Inc. (NYSE:HIMS) Acquired by Virtu Financial LLC

Virtu Financial LLC bought a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 138,105 shares of the company's stock, valued at approximately $3,339,000. Virtu Financial LLC owned approximately 0.06% of Hims & Hers Health at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of HIMS. State Street Corp increased its holdings in shares of Hims & Hers Health by 4.7% in the 3rd quarter. State Street Corp now owns 4,626,543 shares of the company's stock valued at $85,221,000 after acquiring an additional 206,078 shares during the period. Geode Capital Management LLC grew its holdings in shares of Hims & Hers Health by 12.7% during the third quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company's stock worth $79,029,000 after buying an additional 482,177 shares during the last quarter. Wellington Management Group LLP increased its holdings in shares of Hims & Hers Health by 34.5% in the third quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company's stock valued at $63,446,000 after purchasing an additional 883,230 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of Hims & Hers Health by 7.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,796,838 shares of the company's stock worth $43,448,000 after purchasing an additional 129,416 shares during the last quarter. Finally, Yong Rong HK Asset Management Ltd purchased a new stake in shares of Hims & Hers Health in the fourth quarter valued at about $41,104,000. Hedge funds and other institutional investors own 63.52% of the company's stock.

Remove Ads

Hims & Hers Health Trading Down 2.9 %

NYSE HIMS traded down $1.10 on Tuesday, hitting $36.31. 10,307,472 shares of the stock traded hands, compared to its average volume of 13,881,126. The company has a market capitalization of $8.07 billion, a P/E ratio of 82.98 and a beta of 1.37. Hims & Hers Health, Inc. has a twelve month low of $11.20 and a twelve month high of $72.98. The stock has a 50-day moving average of $39.44 and a 200 day moving average of $29.05.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its earnings results on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, topping analysts' consensus estimates of $0.09 by $0.02. The company had revenue of $481.14 million for the quarter, compared to analysts' expectations of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. As a group, equities research analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on HIMS. BTIG Research initiated coverage on Hims & Hers Health in a research note on Tuesday, January 7th. They issued a "buy" rating and a $35.00 target price on the stock. Bank of America boosted their target price on shares of Hims & Hers Health from $21.00 to $22.00 and gave the company an "underperform" rating in a research note on Tuesday, March 18th. Citigroup reiterated a "sell" rating and set a $27.00 price target on shares of Hims & Hers Health in a report on Thursday, March 6th. Leerink Partners raised their target price on shares of Hims & Hers Health from $24.00 to $40.00 and gave the stock a "market perform" rating in a research report on Tuesday, February 25th. Finally, Canaccord Genuity Group increased their price target on Hims & Hers Health from $38.00 to $68.00 and gave the stock a "buy" rating in a research note on Wednesday, February 19th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $37.31.

Insider Activity

In other news, CEO Andrew Dudum sold 128,127 shares of the firm's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $58.27, for a total transaction of $7,465,960.29. Following the completion of the sale, the chief executive officer now directly owns 97,687 shares of the company's stock, valued at $5,692,221.49. This trade represents a 56.74 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Soleil Boughton sold 268,932 shares of Hims & Hers Health stock in a transaction on Monday, January 6th. The stock was sold at an average price of $27.75, for a total value of $7,462,863.00. Following the completion of the transaction, the insider now owns 169,803 shares in the company, valued at $4,712,033.25. The trade was a 61.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 998,244 shares of company stock valued at $35,662,485. Insiders own 17.71% of the company's stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.